Skin Allergy Research Review Issue 7
In this issue:
Clinically orientated recommendations from the EADV for CHE
Meta-analysis suggests upadacitinib is the most efficacious for AD
SCS commonly prescribed for AD against clinical guidelines
LIBERTY-CINDU CUrIADS fails to find a benefit to dupilumab in cold urticaria
Promising efficacy for temtokibart in AD
Abrocitinib bests upadacitinib & baricitinib for AD in real-world
Topical benvitimod suitable for long-term maintenance of CHE
Upadacitinib effective for AD sub-optimally controlled with dupilumab
Positive behavioural changes with omalizumab in solar urticaria
High long-term persistence rates with dupilumab for AD
Expert contributor
Dr Alexis Lara Rivero
Dr Lara Rivero graduated from medical school and completed his postgraduate dermatology training in Venezuela. He worked as a Consultant Dermatologist in both public and private practices in Venezuela, before moving to Australia to continue his work. He combined research and clinical experience and is a member of the Australian Institute of Medical Scientists and […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
These are video files uploaded via YouTube or Vimeo. They will also include page title, summary, author, categories such as clinical area. These will also include relevant publications within the same category.
These are video files uploaded via YouTube or Vimeo. They will also include page title, summary, author, categories such as clinical area. These will also include relevant publications within the same category.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.